African Americans with proximal polyps and overweight or obese women are at higher risk for colorectal cancer: Researchers call for more screening

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 9
Volume 16
Issue 9

Cancer in the proximal colon, the right part of the colon closest to the small intestine, has been increasing in African-American men since the mid-1990s.

WASHINGTON—Cancer in the proximal colon, the right part of the colon closest to the small intestine, has been increasing in African-American men since the mid-1990s.

The rising incidence stands in marked contrast to the overall decrease in colorectal cancer rates seen over the past 20 years, said Ananya Das, MD, associate professor, Division of Gastroenterology, at the Mayo Clinic in Scottsdale, Arizona. Dr. Das presented the findings at the Digestive Disease Week 2007 conference (abstract 431).

Dr. Das and his colleagues analyzed millions of records from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database, calculating sex-, race-, and site-specific incidence for all patients with confirmed, invasive, primary colorectal cancer between 1973 and 2003.

Overall colorectal cancer rates declined during this period in both blacks and whites and in both men and women, the researchers found. But when they looked at proximal colon cancer among African Americans, they "came up with a very startling observation," Dr. Das commented. Starting in the mid-1990s, rates began rising for African Americans, especially men.

Although the reason for the increase is unknown, it does suggest that screening among African Americans should include complete colonoscopies, Dr. Das said. Colonoscopy, in contrast to sigmoidoscopy, includes the proximal section of the colon.

"There are very convincing data that African Americans have lower rates of colonoscopy screening, even after having colon cancer," Dr. Das said. "That could help explain the findings."

Obesity as a risk factor

Risk factors for colorectal cancer may also include obesity and overweight among women, according to another study presented at Digestive Disease Week (abstract 430).

Researchers at the New York University School of Medicine found that among 581 patients referred for screening colonoscopy, men were generally more likely to have polyps of any size.

However, women in the study who were overweight (defined as a body mass index of 25 to 29.9) or obese (defined as body mass index of 30 or higher) had rates similar to that of the men (see Figure below).

Among the overweight and obese women, the prevalence of polyps was 13%, compared with 14.6% for men, and the prevalence of advanced neoplasms was 18.6% for women, compared with 18% for men.

Women of normal weight (body mass index of 18 to 24) were significantly less likely to have polyps of any size.

"What this tells us is that we can use body mass index as a way to further risk stratify women and to encourage colorectal screening," said senior author Fritz Francois, MD, assistant professor, Division of gastroenterology, at New York University Medical School.

Not enough colonoscopies?

Dr. Das concurred. "We may not be doing enough colonoscopies," he said, when discussing his group's findings in African-American men. "We need to take a new look at the screening recommendations."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
Related Content